Laurent Sallé
ORCID:
0000-0003-0069-2951
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
A5103125876
Research Areas
- Malaria Research and Control
- Mosquito-borne diseases and control
- Herpesvirus Infections and Treatments
Sanofi (France)
2021
James M. Murithi
Cécile Pascal
Jade Bath
Xavier Boulenc
Nina F. Gnädig
and 50
more
Charisse Flerida A. Pasaje
Kelly Rubiano
Tomas Yeo
Sachel Mok
Sylvie Klieber
Paul Désert
Marı́a Belén Jiménez-Dı́az
Jutta Marfurt
Mélanie Rouillier
Mohammed H. Cherkaoui‐Rbati
Nathalie Gobeau
Sergio Wittlin
Anne‐Catrin Uhlemann
Ric N. Price
Grennady Wirjanata
Rintis Noviyanti
Patrick K. Tumwebaze
Roland A. Cooper
Philip J. Rosenthal
Laura M. Sanz
Francisco‐Javier Gamo
Jayan T. Joseph
Shivendra V. Singh
Sridevi Bashyam
Jean‐Michel Augereau
Elie Giraud
Tanguy Bozec
Vermat Thierry
Gilles Tuffal
Jean-Michel Guillon
J. Ménégotto
Laurent Sallé
Guillaume Louit
Marie‐José Cabanis
Marie Françoise Nicolas
Michel Doubovetzky
Rita Merino
Nadir Bessila
Íñigo Angulo‐Barturen
Delphine Baud
Lidiya Bebrevska
Fanny Escudié
Jacquin C. Niles
Benjamin Blasco
Simon F. Campbell
Gilles Courtemanche
Laurent Fraisse
Alain Pellet
David A. Fidock
Didier Leroy
The emergence and spread of Plasmodium falciparum resistance to first-line antimalarials creates an imperative identify develop potent preclinical candidates with distinct modes action. Here, we report the identification MMV688533, acylguanidine that was developed following a whole-cell screen compounds known hit high-value targets in human cells. MMV688533 displays fast parasite clearance vitro is not cross-resistant antimalarials. In P. NSG mouse model, long-lasting pharmacokinetic profile...
10.1126/scitranslmed.abg6013
article
EN
Science Translational Medicine
2021-07-21
Coming Soon ...